Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countr...
Sanofi-Blueprint deal is a bullish signal about biotech M&A
The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. ...
Sanofi doubles down on immunology with $9.1bn Blueprint deal
Sanofi SA (ADR) (NYSE:SNY) is placing a major bet on rare immune disorders with its $9.1bn acquisition of US biotech firm Blueprint Medicines, part of a wider push to become a global leader in immu...
Sanofi buys US biopharma group Blueprint in $9.1 bln deal
French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companie...
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment
Sanofi faces setbacks after itepekimab's Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Despite challenges, Sanofi is attractively valued, with my DCF a...
Itepekimab Failure A Setback For Sanofi And Regeneron
Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower pe...
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials
Sanofi and Regeneron said that drug candidate Itepekimab didn't meet primary endpoint in a phase three study, although a benefit was seen earlier in the trial.
US FDA approves use of Sanofi's meningococcal vaccine in infants
French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group.
C4X Discovery receives latest milestone payment from Sanofi
€8 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme
Sanofi, VNVC launch vaccine factory in Vietnam
Sanofi and Vietnam Vaccine JSC, or VNVC, on Tuesday launched a vaccine manufacturing facility in Vietnam, aimed at producing vaccines for domestic use and export.
Press Release: Sanofi completes acquisition of DR-0201
Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a privat...
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
Related Companies